- Home
- JGH vs CRMD Comparison
JGH vs CRMD Comparison
Compare JGH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- CRMD
- Stock Information
- Founded
- JGH 2014
- CRMD 2006
- Country
- JGH United States
- CRMD United States
- Employees
- JGH N/A
- CRMD N/A
- Industry
- JGH Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- CRMD Health Care
- Exchange
- JGH Nasdaq
- CRMD Nasdaq
- Market Cap
- JGH 292.3M
- CRMD 973.3M
- IPO Year
- JGH N/A
- CRMD 2010
- Fundamental
- Price
- JGH $13.05
- CRMD $11.59
- Analyst Decision
- JGH
- CRMD Strong Buy
- Analyst Count
- JGH 0
- CRMD 7
- Target Price
- JGH N/A
- CRMD $17.33
- AVG Volume (30 Days)
- JGH 73.9K
- CRMD 2.5M
- Earning Date
- JGH 01-01-0001
- CRMD 08-13-2025
- Dividend Yield
- JGH 9.85%
- CRMD N/A
- EPS Growth
- JGH N/A
- CRMD N/A
- EPS
- JGH N/A
- CRMD 0.28
- Revenue
- JGH N/A
- CRMD $82,553,827.00
- Revenue This Year
- JGH N/A
- CRMD $238.38
- Revenue Next Year
- JGH N/A
- CRMD $53.52
- P/E Ratio
- JGH N/A
- CRMD $41.79
- Revenue Growth
- JGH N/A
- CRMD N/A
- 52 Week Low
- JGH $10.36
- CRMD $3.61
- 52 Week High
- JGH $12.85
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- JGH 73.00
- CRMD 39.28
- Support Level
- JGH $12.53
- CRMD $12.14
- Resistance Level
- JGH $12.81
- CRMD $17.43
- Average True Range (ATR)
- JGH 0.10
- CRMD 0.74
- MACD
- JGH 0.03
- CRMD -0.49
- Stochastic Oscillator
- JGH 92.36
- CRMD 2.42
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.